During this webinar Silvia Comis, MD, head of Clinical Development at OSE Immunotherapeutics will present OSE2101(also known as Tedopi®) and the ARTEMIA clinical trial, a registrational Phase III clinical trial of OSE2101 in non-small cell lung cancer. OSE2101 is a therapeutic cancer vaccine developed by OSE Immunotherapeutics and designed to induce a specific lymphocyte response in the body that can fight cancers that express the antigens present in the vaccine. As the synthetic antigens in OSE2101 are specifically targeted to HLA-A2 (Human Leucocytes Antigen-A2 superfamily) receptors present on the surface of cells, the targeted therapy requires a companion diagnostic solution.
Valentina Manzini, PhD, Project coordinator Companion Diagnostics, will provide a description of the companion diagnostic solution GenDx CDx Tedopi, developed to aid in the identification of HLA-A*02 positive subjects for the ARTEMIA trial, who may be eligible for treatment with OSE Immunotherapeutics’ investigational drug, OSE2101.
